Cargando…

Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients

In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples i...

Descripción completa

Detalles Bibliográficos
Autores principales: Postina, Patricia, Skladny, Julian, Boch, Tobias, Cornely, Oliver A., Hamprecht, Axel, Rath, Peter-Michael, Steinmann, Jörg, Bader, Oliver, Miethke, Thomas, Dietz, Anne, Merker, Natalia, Hofmann, Wolf-Karsten, Buchheidt, Dieter, Spiess, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890139/
https://www.ncbi.nlm.nih.gov/pubmed/29662479
http://dx.doi.org/10.3389/fmicb.2018.00555
_version_ 1783312811311497216
author Postina, Patricia
Skladny, Julian
Boch, Tobias
Cornely, Oliver A.
Hamprecht, Axel
Rath, Peter-Michael
Steinmann, Jörg
Bader, Oliver
Miethke, Thomas
Dietz, Anne
Merker, Natalia
Hofmann, Wolf-Karsten
Buchheidt, Dieter
Spiess, Birgit
author_facet Postina, Patricia
Skladny, Julian
Boch, Tobias
Cornely, Oliver A.
Hamprecht, Axel
Rath, Peter-Michael
Steinmann, Jörg
Bader, Oliver
Miethke, Thomas
Dietz, Anne
Merker, Natalia
Hofmann, Wolf-Karsten
Buchheidt, Dieter
Spiess, Birgit
author_sort Postina, Patricia
collection PubMed
description In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A, and M220 in the Aspergillus fumigatus (A. fumigatus) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius® real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates (n = 3) of immunocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known Cyp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61% in biopsies, 29% in CSF, 67% in BAL samples and 100% in isolates. In comparison the amount of positive PCRs using the AsperGenius® assays was 47% in biopsies, 42% in CSF, 59% in BAL samples and 100% in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius® system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius® system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies.
format Online
Article
Text
id pubmed-5890139
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58901392018-04-16 Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients Postina, Patricia Skladny, Julian Boch, Tobias Cornely, Oliver A. Hamprecht, Axel Rath, Peter-Michael Steinmann, Jörg Bader, Oliver Miethke, Thomas Dietz, Anne Merker, Natalia Hofmann, Wolf-Karsten Buchheidt, Dieter Spiess, Birgit Front Microbiol Microbiology In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A, and M220 in the Aspergillus fumigatus (A. fumigatus) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius® real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates (n = 3) of immunocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known Cyp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61% in biopsies, 29% in CSF, 67% in BAL samples and 100% in isolates. In comparison the amount of positive PCRs using the AsperGenius® assays was 47% in biopsies, 42% in CSF, 59% in BAL samples and 100% in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius® system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius® system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies. Frontiers Media S.A. 2018-03-27 /pmc/articles/PMC5890139/ /pubmed/29662479 http://dx.doi.org/10.3389/fmicb.2018.00555 Text en Copyright © 2018 Postina, Skladny, Boch, Cornely, Hamprecht, Rath, Steinmann, Bader, Miethke, Dietz, Merker, Hofmann, Buchheidt and Spiess. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Postina, Patricia
Skladny, Julian
Boch, Tobias
Cornely, Oliver A.
Hamprecht, Axel
Rath, Peter-Michael
Steinmann, Jörg
Bader, Oliver
Miethke, Thomas
Dietz, Anne
Merker, Natalia
Hofmann, Wolf-Karsten
Buchheidt, Dieter
Spiess, Birgit
Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title_full Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title_fullStr Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title_full_unstemmed Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title_short Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
title_sort comparison of two molecular assays for detection and characterization of aspergillus fumigatus triazole resistance and cyp51a mutations in clinical isolates and primary clinical samples of immunocompromised patients
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890139/
https://www.ncbi.nlm.nih.gov/pubmed/29662479
http://dx.doi.org/10.3389/fmicb.2018.00555
work_keys_str_mv AT postinapatricia comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT skladnyjulian comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT bochtobias comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT cornelyolivera comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT hamprechtaxel comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT rathpetermichael comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT steinmannjorg comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT baderoliver comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT miethkethomas comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT dietzanne comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT merkernatalia comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT hofmannwolfkarsten comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT buchheidtdieter comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients
AT spiessbirgit comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients